Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022)
Neurogene posted quarterly Preferred Stock Liabilities of $244.4 million for Q4 2022, up 752.19% year-on-year from $28.7 million in Q4 2021, and up 752.19% on a QoQ basis from $28.7 million in Q4 2021.
Neurogene (NGNE) has 3 years of Preferred Stock Liabilities data on file, last reported at $244.4 million in Q4 2022.
- For the quarter ending Q4 2022, Preferred Stock Liabilities rose 752.19% year-over-year to $244.4 million; the trailing twelve-month figure through Dec 2022 stood at $244.4 million (up 752.19% YoY), and the FY2022 full-year result was $244.4 million, up 752.19% from the prior year.
- Preferred Stock Liabilities for Q4 2022 stood at $244.4 million, up from $28.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $244.4 million in Q4 2022 and bottomed at $28.7 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 244.37 Mn |
| Dec 31, 2021 | 28.68 Mn |
| Dec 31, 2013 | 73.86 Mn |